Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential
Journal of Medicinal Chemistry · 24.07.2025 · 68 (14) · 14171-14194
DOI: 10.1021/acs.jmedchem.5c01677 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.07.2025. Verfasst von Alessia Raucci und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Hydrazines. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell?Istruzione, dell?Universit? e della Ricerca, Sapienza Universit? di Roma, Ministero della Salute.
Abstract (Originalsprache)
Histone deacetylase (HDAC) impairment is strongly related to various cancers as well as neurodegenerative and inflammatory diseases. Considering HDACs' crucial role as drug targets, over the past decade, the development of HDAC inhibitors (HDACi) has gained significant interest in the pharmaceutical field. To date, five HDAC inhibitors have been approved by the FDA, and many are currently in clinical trials. Despite the common use of hydroxamic acid and 2-aminoanilide groups as zinc-binding groups (ZBGs) in HDAC inhibitors, concerns about their instability, toxicity, and low bioavailability have led researchers to explore alternative ZBGs. Recently, the hydrazide group has emerged as a promising alternative, offering potentially safer properties and fewer off-target effects. This perspective will discuss recent advancements from a medicinal chemistry point of view related to the hydrazide group's role in HDAC inhibitor development, highlighting their pharmaceutical properties, biological activities, and potential benefits in reducing side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
- Pasteur Institute, Cenci-Bolognetti Foundation, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.
ORCID-Profile: Clemens Zwergel, Sergio Valente, Antonello Mai
Förderung
- Ministero dell?Istruzione, dell?Universit? e della Ricerca
- Sapienza Universit? di Roma
- Ministero della Salute
- European Social Fund Plus
- Artificial Intelligence, Robotics, and Control
Zitieren
APA
Raucci, A., Zwergel, C., Valente, S., & Mai, A. (2025). Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential. Journal of Medicinal Chemistry, 68(14), 14171-14194. https://doi.org/10.1021/acs.jmedchem.5c01677
Vancouver
Raucci A, Zwergel C, Valente S, Mai A. Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential. Journal of Medicinal Chemistry. 2025;68(14):14171-14194. doi:10.1021/acs.jmedchem.5c01677
BibTeX
@article{Raucci2025,
author = {Raucci, Alessia and Zwergel, Clemens and Valente, Sergio and Mai, Antonello},
title = {Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {14},
pages = {14171--14194},
doi = {10.1021/acs.jmedchem.5c01677}
}
EUVIMED